Their relevance to hair is entirely systemic and indirect
If approved, we believe pemvidutide could offer an important option for obesity patients, including those with risk factors for cardiovascular disease. However, tolerability issues remain, as the trial led to one participant experiencing vomiting, and 4.1% of the patients in the drug cohort discontinuing treatment in the first 16 weeks, when compared to 2.1% in the placebo group
Malar J 6(1):253 LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S et al (2014) Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency
Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances [PMID: 11978191] Laboratory literature summary: Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances